Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
16 "Neutropenia"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
Seul-Gi Kim, Min Hwan Kim, Sejung Park, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Byeong Woo Park, Seung Il Kim, Jung Hwan Ji, Joon Jeong, Kabsoo Shin, Jieun Lee, Hyung-Don Kim, Kyung Hae Jung, Joohyuk Sohn
Cancer Res Treat. 2023;55(4):1198-1209.   Published online April 11, 2023
DOI: https://doi.org/10.4143/crt.2022.1543
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia.
Materials and Methods
Patients with HR-positive, human epidermal growth factor receptor 2–negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups.
Results
During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality.
Conclusion
Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies
    Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam
    Targeted Oncology.2025; 20(1): 71.     CrossRef
  • Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real‐World Data
    Alieke K. Bos, Annelieke E.C.A.B. Willemsen, Loes E. Visser, Lennart J. Stoker, Jurjen S. Kingma, Mirjam K. Rommers, Emile M. Kuck, Paul D. van der Linden, Merel van Nuland
    Clinical Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Palbociclib

    Reactions Weekly.2023; 1988(1): 138.     CrossRef
  • 4,121 View
  • 271 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
Yong Wha Moon, Seung Ki Kim, Keun Seok Lee, Moon Hee Lee, Yeon Hee Park, Kyong Hwa Park, Gun Min Kim, Seungtaek Lim, Seung Ah Lee, Jae Duk Choi, Eunhye Baek, Hyesun Han, Seungjae Baek, Seock-Ah Im
Cancer Res Treat. 2023;55(3):766-777.   Published online January 19, 2023
DOI: https://doi.org/10.4143/crt.2022.987
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We investigated the consistent efficacy and safety of eflapegrastim, a novel long-acting granulocyte-colony stimulating factor (G-CSF), in Koreans and Asians compared with the pooled population of two global phase 3 trials.
Materials and Methods
Two phase 3 trials (ADVANCE and RECOVER) evaluated the efficacy and safety of fixed-dose eflapegrastim (13.2 mg/0.6 mL [3.6 mg G-CSF equivalent]) compared to pegfilgrastim (6 mg based on G-CSF) in breast cancer patients who received neoadjuvant or adjuvant docetaxel/cyclophosphamide. The primary objective was to demonstrate non-inferiority of eflapegrastim compared to pegfilgrastim in mean duration of severe neutropenia (DSN) in cycle 1, in Korean and Asian subpopulations.
Results
Among a total of 643 patients randomized to eflapegrastim (n=314) or pegfilgrastim (n=329), 54 Asians (29 to eflapegrastim and 25 to pegfilgrastim) including 28 Koreans (14 to both eflapegrastim and pegfilgrastim) were enrolled. The primary endpoint, DSN in cycle 1 in the eflapegrastim arm was non-inferior to the pegfilgrastim arm in Koreans and Asians. The DSN difference between the eflapegrastim and pegfilgrastim arms was consistent across populations: –0.120 days (95% confidence interval [CI], –0.227 to –0.016), –0.288 (95% CI, –0.714 to 0.143), and –0.267 (95% CI, –0.697 to 0.110) for pooled population, Koreans and Asians, respectively. There were few treatment-related adverse events that caused discontinuation of eflapegrastim (1.9%) or pegfilgrastim (1.5%) in total and no notable trends or differences across patient populations.
Conclusion
This study may suggest that eflapegrastim showed non-inferior efficacy and similar safety compared to pegfilgrastim in Koreans and Asians, consistently with those of pooled population.

Citations

Citations to this article as recorded by  
  • Comparison of Prophylactic Efficacy of Eflapegrastim and Pegteograstim for Chemotherapy-induced Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX/mFOLFIRINOX
    Eui Seon Lee, Min Jung Geum, Jong Hee Ko, Jae Song Kim, Eun Sun Son, Yun Mi Yu
    Journal of Korean Society of Health-System Pharmacists.2024; 41(3): 253.     CrossRef
  • 4,690 View
  • 273 Download
  • 1 Crossref
Close layer
Hematologic malignancy
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
Do Young Kim, Jehyun Nam, Joo-Seop Chung, Byeol Eun Jeon, Ji Hyun Lee, Jae-Cheol Jo, Sang-Woo Kim, Ho-Jin Shin
Cancer Res Treat. 2022;54(4):1256-1267.   Published online December 31, 2021
DOI: https://doi.org/10.4143/crt.2021.944
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Pegfilgrastim is widely used to prevent chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) in patients with diffuse large B-cell lymphoma (DLBCL). We investigated the predictive factors affecting CIN and FN incidence in patients with DLBCL receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy with pegfilgrastim and conducted experiments to find reason for the occurrence of CIN even when pegfilgrastim was used.
Materials and Methods
We reviewed the CIN and FN events of 200 patients with DLBCL. Based on these data, we investigate the association with predictive factor and the levels of granulocyte-colony stimulating factor (G-CSF) receptor signaling pathway markers (pSTAT3, pAKT, pERK1/2, pBAD, and CXCR4) in bone marrow (BM) samples isolated from patients with DLBCL.
Results
FN was significantly associated with stage III/IV (hazard ratio [HR], 12.74) and low serum albumin levels (HR, 3.87). Additionally, patients with FN had lower progression-free survival (PFS; 2-year PFS, 51.1 % vs. 74.0%) and overall survival (OS; 2-year OS, 58.2% vs. 85.0%) compared to those without FN. The occurrence of CIN was associated with overexpression of G-CSF receptor signaling pathway markers, and expression levels of these markers were upregulated in BM cells co-cultured with DLBCL cells. The rate of neutrophil apoptosis was also higher in neutrophils co-cultured with DLBCL cells and was further promoted by treatment with doxorubicin.
Conclusion
Our findings suggest that high DLBCL burden may alter the BM environment and G-CSF receptor signaling pathway, even in chemotherapy-naïve state, which may increase CIN frequency during R-CHOP chemotherapy.

Citations

Citations to this article as recorded by  
  • Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma
    Åsa Lindberg, Åsa Johansson, Fredrik Kahn, Göran Jönsson, Mats Jerkeman
    Hematological Oncology.2025;[Epub]     CrossRef
  • Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study
    Masaya Morimoto, Yuma Yokoya, Kikuaki Yoshida, Hideki Kosako, Yoshikazu Hori, Toshiki Mushino, Shinobu Tamura, Reiko Ito, Ryosuke Koyamada, Takuya Yamashita, Shinichiro Mori, Nobuyoshi Mori, Sachiko Ohde
    Hematology Reports.2024; 16(1): 76.     CrossRef
  • Multi‐omics integration reveals the oncogenic role of eccDNAs in diffuse large B‐cell lymphoma through STING signalling
    Zijuan Wu, Wei Zhang, Luqiao Wang, Jiayan Leng, Yongle Li, Zhou Fan, Mengtao Zhan, Lei Cao, Yongning Jiang, Yan Jiang, Bing Sun, Jianxin Fu, Jianyong Li, Wenyu Shi, Hui Jin
    Clinical and Translational Medicine.2024;[Epub]     CrossRef
  • Transcriptomic analysis of neutrophil apoptosis induced by diffuse large B-cell lymphoma unveils a potential role in neutropenia
    Byeol-Eun Jeon, Ji-Eun Lee, Jungwook Park, Hyejung Jung, Eun Gyung Park, Du Hyeong Lee, Young-Su Seo, Heui-Soo Kim, Ho-Jin Shin, Sang-Woo Kim
    Genes & Genomics.2023; 45(8): 1013.     CrossRef
  • 6,056 View
  • 183 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Pediatric cancer
Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
Ji Won Lee, Joon Seol Bae, Jin Ho Kim, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Hong Hoe Koo, Sook-young Woo, Seonwoo Kim, Ki Woong Sung
Cancer Res Treat. 2022;54(1):259-268.   Published online April 12, 2021
DOI: https://doi.org/10.4143/crt.2021.010
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We performed this study to determine whether the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker of individual susceptibility to chemotherapeutic agents affecting treatment outcome in patients with neuroblastoma.
Materials and Methods
The study included 313 patients who received the first cycle chemotherapy with a CEDC (cisplatin+etoposide+doxorubicin+cyclophosphamide) regimen and had absolute neutrophil count (ANC) data available. The cumulative incidences of progression and treatment-related mortality (TRM) were estimated. To identify genetic variations associated with the ANC, a genome-wide association study (GWAS) was performed.
Results
An ANC of 32.5/μL was determined as the cutoff point to categorize patients into the good and poor prognosis subgroups in terms of progression. Patients with a high nadir ANC had a higher cumulative incidence of progression than those with a low nadir ANC (p < 0.001). In multivariate analysis, high nadir ANC, age, bone marrow involvement, and unfavorable histology were poor prognostic factors. With regard to the TRM, patients with a low nadir ANC (ANC < 51.0/μL) had a higher cumulative incidence of TRM than those with a high nadir ANC (p=0.010). In GWAS, single-nucleotide polymorphisms of LPHN2 and CRHR1 were significantly associated with the nadir ANC.
Conclusion
In neuroblastoma patients, the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker to predict an individual’s susceptibility to chemotherapeutic agents. Tailoring of treatment based on the degree of neutropenia needs to be considered.

Citations

Citations to this article as recorded by  
  • Impact of 10% Dose Reductions and Duration of Treatment Delays in the Management of Chemotherapy‐Induced Neutropenia in Dogs Treated With Common Chemotherapy Protocols: A Single‐Centre Experience
    Suzanne Busser, Laura Blackwood, Constanza Pereira, Margo Chase‐Topping, Spela Bavcar, Quentin Fournier
    Veterinary and Comparative Oncology.2024; 22(4): 542.     CrossRef
  • Targeting the myeloid microenvironment in neuroblastoma
    Marjolein C. Stip, Loes Teeuwen, Miranda P. Dierselhuis, Jeanette H. W. Leusen, Daniëlle Krijgsman
    Journal of Experimental & Clinical Cancer Research.2023;[Epub]     CrossRef
  • 6,443 View
  • 163 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
Hyery Kim, Heewon Seo, Yoomi Park, Byung-Joo Min, Myung-Eui Seo, Kyung Duk Park, Hee Young Shin, Ju Han Kim, Hyoung Jin Kang
Cancer Res Treat. 2018;50(3):823-834.   Published online September 4, 2017
DOI: https://doi.org/10.4143/crt.2017.351
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mercaptopurine (MP) is one of the main chemotherapeutics for acute lymphoblastic leukemia (ALL). To improve treatment outcomes, constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. We performed two-stage analyses to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients.
Materials and Methods
Targeted sequencing of 40 patients who exhibited definite MP intolerance was conducted using a novel panel of 211 pharmacogenetic-related genes, and subsequent analysis was performed with 185 patients.
Results
Using bioinformatics tools and genetic data, four functionally interesting variants were selected (ABCC4, APEX1, CYP1A1, and CYP4F2). Including four variants, 23 variants in 12 genes potentially linked to MP adverse reactions were selected as final candidates for subsequent analysis in 185 patients. Ultimately, a variant allele in APEX1 rs2307486was found to be strongly associated with MP-induced neutropenia that occurred within 28 days of initiating MP (odds ratio, 3.44; p=0.02). Moreover, the cumulative incidence of MP-related neutropenia was significantly higher in patients with APEX1 rs2307486 variants, as GG genotypes were associated with the highest cumulative incidence (p < 0.01). NUDT15 rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01).
Conclusion
We have identified that APEX1 rs2307486 variants conferred an increased risk of MP-related early onset neutropenia. APEX1 and NUDT15 both contribute to cell protection from DNA damage or misincorporation, so alleles that impair the function of either gene may affect MP sensitivities, thereby inducing MP-related neutropenia.

Citations

Citations to this article as recorded by  
  • Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response
    Ashwin Kamath, Suresh Kumar Srinivasamurthy, Mukta N. Chowta, Sheetal D. Ullal, Youssef Daali, Uppugunduri S. Chakradhara Rao
    Pharmaceuticals.2022; 15(8): 990.     CrossRef
  • The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia
    Jae Min Lee, Ye Jee Shim, Do-Hoon Kim, Nani Jung, Jung-Sook Ha
    Children.2021; 8(3): 224.     CrossRef
  • Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT
    Hyery Kim, Seungwon You, Yoomi Park, Jung Yoon Choi, Youngeun Ma, Kyung Tak Hong, Kyung-Nam Koh, Sunmin Yun, Kye Hwa Lee, Hee Young Shin, Suehyun Lee, Keon Hee Yoo, Ho Joon Im, Hyoung Jin Kang, Ju Han Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China
    Gangling Pu, Yali Wang, Shaoqin Duan, Jingpei Chen, Chunhui Yang, Tingting Cui, Chunlian Fang, Yan Zhou, Han Zhang, Xin Tian
    Pediatrics International.2021; 63(7): 790.     CrossRef
  • A Dual Face of APE1 in the Maintenance of Genetic Stability in Monocytes: An Overview of the Current Status and Future Perspectives
    Gabriela Betlej, Ewelina Bator, Antoni Pyrkosz, Aleksandra Kwiatkowska
    Genes.2020; 11(6): 643.     CrossRef
  • Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT
    Yoomi Park, Hyery Kim, Heewon Seo, Jung Yoon Choi, Youngeun Ma, Sunmin Yun, Byung-Joo Min, Myung-Eui Seo, Keon Hee Yoo, Hyoung Jin Kang, Ho Joon Im, Ju Han Kim
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology
    Emma C. Bernsen, Melanie M. Hagleitner, Theodorus W. Kouwenberg, Lidwien M. Hanff
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens: a single-center analysis
    Ho Jung Choi, Juhee Shin, Sunghan Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
    BLOOD RESEARCH.2020; 55(4): 262.     CrossRef
  • NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia
    Eun Sang Yi, Young Bae Choi, Rihwa Choi, Na Hee Lee, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Soo-Youn Lee, Hong Hoe Koo
    Cancer Research and Treatment.2018; 50(3): 872.     CrossRef
  • 23,927 View
  • 333 Download
  • 12 Web of Science
  • 9 Crossref
Close layer
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
Cheng Xu, Shi-Ping Yang, Yuan Zhang, Ling-Long Tang, Guan-Qun Zhou, Xu Liu, Yan-Ping Mao, Rui Guo, Wen-Fei Li, Lei Chen, Ai-Hua Lin, Ying Sun, Jun Ma
Cancer Res Treat. 2018;50(3):777-790.   Published online July 24, 2017
DOI: https://doi.org/10.4143/crt.2017.255
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLRmin). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLRmin on OS/DFS.
Results
Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLRmin (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLRmin ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect.
Conclusion
Occurrence of neutropenia, number of myelosuppression events, and high post-NLRmin during PF/TP IC-1 have prognostic value for poor survival in LANPC.

Citations

Citations to this article as recorded by  
  • Prospective clinical study of the efficacy and safety of different doses of PEG recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventing leukopenia/neutropenia caused by concurrent chemoradiotherapy for cervical cancer
    Tingting Yu, Yiwei Zhang, Jiawen Li, Zhuo Li, Rui Tong
    Holistic Integrative Oncology.2024;[Epub]     CrossRef
  • Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma
    Lu‐Lu Zhang, Xi Chen, Ying‐Ying Huang, Chi‐Xiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jia‐Yu Zhou, Hao‐Yang Huang, Xiang Guo, Xing Lv
    Cancer Medicine.2023; 12(13): 14084.     CrossRef
  • Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)
    Jun Wang, Baosheng Li
    Precision Radiation Oncology.2023; 7(3): 150.     CrossRef
  • Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition)
    Jun Wang, Baosheng Li
    Precision Radiation Oncology.2021; 5(1): 4.     CrossRef
  • Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma
    Yuanji Xu, Zijie Wu, Wangzhong Ye, Youping Xiao, Wei Zheng, Qinyan Chen, Penggang Bai, Zhizhong Lin, Chuanben Chen
    BMC Cancer.2021;[Epub]     CrossRef
  • Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
    Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
    IEEE Access.2021; 9: 98701.     CrossRef
  • Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma
    Dan Ou, Xiaoshen Wang, Mingyao Wu, Fen Xue, Yujiao Li, Chaosu Hu, Xiayun He
    Strahlentherapie und Onkologie.2020; 196(3): 252.     CrossRef
  • Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound
    Wei Wang, Dong Luo, Junlin Chen, Jinyun Chen, Yi Xia, Wenzhi Chen, Yan Wang
    Bioscience Reports.2020;[Epub]     CrossRef
  • 12,091 View
  • 241 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Case Report
Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
Hyun Sun Woo, Kyoung Hwa Lee, Phill Hoon Yoon, Su Ji Kim, Inkeun Park, Young Saing Kim, Hee Kyung Ahn, Junshik Hong, Dong Bok Shin, Sun Jin Sym
Cancer Res Treat. 2015;47(4):949-953.   Published online October 28, 2014
DOI: https://doi.org/10.4143/crt.2014.052
AbstractAbstract PDFPubReaderePub
Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immunemediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.

Citations

Citations to this article as recorded by  
  • Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies
    Ju Li, Wanqing Wang, Kaipeng Jiang, Jiuwei Cui, Chang Wang, Tingting Liang, Yizhuo Wang, Shuhan Liu, Wenshuo Zhou
    Journal of Gastrointestinal Cancer.2024; 55(3): 1144.     CrossRef
  • Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report
    Khin Pyai, David I LeRoy, Joseph Attallah, Hosam Hakim, Zyad Kafri
    Cureus.2024;[Epub]     CrossRef
  • The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients
    Marek Kos, Piotr Tomaka, Paulina Mertowska, Sebastian Mertowski, Julia Wojnicka, Anna Błażewicz, Ewelina Grywalska, Krzysztof Bojarski
    Journal of Clinical Medicine.2024; 13(22): 6738.     CrossRef
  • Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature
    You Zou, Shuang Liu, Jianhong Wu, Zhen Sun
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • A case of idiosyncratic liver injury after oxaliplatin‐induced thrombocytopenia
    Shinji Honda, Masayuki Tsujimoto, Tetsuya Minegaki, Tomohiko Mori, Junji Muraoka, Kohshi Nishiguchi
    Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 373.     CrossRef
  • Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents
    Benjamin K. Gersten, Tracy S. Fitzgerald, Katharine A. Fernandez, Lisa L. Cunningham
    Journal of the Association for Research in Otolaryngology.2020; 21(4): 303.     CrossRef
  • Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms
    Haider Ghazanfar, Iqra Nawaz, Nisha Ali
    Cureus.2020;[Epub]     CrossRef
  • Oxaliplatin Treatment Alters Systemic Immune Responses
    Vanesa Stojanovska, Monica Prakash, Rachel McQuade, Sarah Fraser, Vasso Apostolopoulos, Samy Sakkal, Kulmira Nurgali
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study
    Katia Bencardino, Gianluca Mauri, Alessio Amatu, Federica Tosi, Erica Bonazzina, Laura Palmeri, Marialuisa Querques, Federica Ravera, Alberto Menegotto, Elisa Boiani, Andrea Sartore-Bianchi, Salvatore Siena
    Clinical Colorectal Cancer.2016; 15(3): 213.     CrossRef
  • 12,768 View
  • 116 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Original Articles
The Usefulness of Procalcitonin and C-Reactive Protein as Early Diagnostic Markers of Bacteremia in Cancer Patients with Febrile Neutropenia
Dae Yong Kim, Yoon-Seon Lee, Shin Ahn, Yeon Hee Chun, Kyung Soo Lim
Cancer Res Treat. 2011;43(3):176-180.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.176
AbstractAbstract PDFPubReaderePub
PURPOSE
Procalcitonin (PCT) and C-reactive protein (CRP) are well known inflammatory markers. This study was designed to determine whether PCT and CRP are useful as early diagnostic markers for bacteremia in cancer patients with febrile neutropenia (FN) in the emergency department (ED).
MATERIALS AND METHODS
In this retrospective study, 286 episodes of FN in the ED were consecutively included between June 2009 and August 2010. From medical records, clinical characteristics including PCT and CRP were extracted and analyzed.
RESULTS
Bacteremia was identified in 38 (13.3%) of the 286 episodes. The median values of PCT (2.8 ng/mL vs. 0.0 ng/mL, p=0.000) and CRP (15.9 mg/dL vs. 5.6 mg/dL, p=0.002) were significantly higher in the group with bacteremia compared to the group without bacteremia. In univariate analysis, elevated PCT (>0.5 ng/mL) and CRP (>10 mg/dL) as well as older age, hypotension, tachycardia, tachypnea, and high body temperature were significantly associated with bacteremia. On multivariate analysis, elevated PCT (>0.5 ng/mL) (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.4 to 9.2; p<0.01) and tachypnea (OR, 3.4; 95% CI, 1.4 to 8.5; p<0.01) were independent early diagnostic markers for bacteremia in FN patients. The area under the curve of PCT was 74.8% (95% CI, 65.1 to 84.6%) and that of CRP was 65.5% (95% CI, 54.8 to 76.1%). With a PCT cut-off value of 0.5 ng/mL, sensitivity and specificity were 60.5% and 82.3%, respectively, while the sensitivity and specificity were 57.6% and 67.3%, respectively, with a CRP cutoff of 10 mg/dL.
CONCLUSION
These findings suggest that PCT is a useful early diagnostic marker for the detection of bacteremia in FN at the ED and has better diagnostic value than CRP.

Citations

Citations to this article as recorded by  
  • The utility of procalcitonin for diagnosing bacteremia and bacterial pneumonia in hospitalized oncology patients
    Mary K. Munsell, Temidayo Fadelu, Sherri O. Stuver, Katherine P. Baker, Brett Glotzbecker, Justin L. Simmons, Kerry L. Reynolds, Ami K. Patel
    Journal of Cancer Research and Clinical Oncology.2023; 149(8): 5193.     CrossRef
  • Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases
    May Nasser Bin-Jumah, Muhammad Shahid Nadeem, Sadaf Jamal Gilani, Bismillah Mubeen, Inam Ullah, Sami I. Alzarea, Mohammed M. Ghoneim, Sultan Alshehri, Fahad A. Al-Abbasi, Imran Kazmi
    Antioxidants.2022; 11(2): 232.     CrossRef
  • Current Status of Antibiotic Stewardship and the Role of Biomarkers in Antibiotic Stewardship Programs
    Chung-Jong Kim
    Infection & Chemotherapy.2022; 54(4): 674.     CrossRef
  • Profile of febrile neutropenia in childhood cancer patients and the clinical utility of procalcitonin and C-reactive protein in identifying severe infections
    Latha Sneha, Sunitha Ramasamy, Vidya Krishna, Uma Sekar, Kopula Sathyamoorthy Sridharan, Shruti Krishna Iyengar, Julius Xavier Scott, Dhaarani Jayaraman
    Sri Ramachandra Journal of Health Sciences.2022; 2: 61.     CrossRef
  • Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms
    Ivan Krečak, Nena Peran, Ivana Lapić, Velka Gverić-Krečak, Filip Krečak, Pavle Rončević, Nadira Duraković
    Wiener klinische Wochenschrift.2021; 133(1-2): 62.     CrossRef
  • Presepsin and Midregional Proadrenomedullin in Pediatric Oncologic Patients with Febrile Neutropenia
    Luisa Agnello, Giulia Bivona, Elisa Parisi, Giuseppe Dejan Lucido, Alessandro Iacona, Anna Maria Ciaccio, Rosaria Vincenza Giglio, Ottavio Ziino, Marcello Ciaccio
    Laboratory Medicine.2020; 51(6): 585.     CrossRef
  • Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile neutropenia in hematology patients- an experience from a tertiary care center in Northern India
    Rohan Halder, Tulika Seth, Pradeep K. Chaturvedi, Priyanka Mishra, Manoranjan Mahapatra, Hara P. Pati, Seema Tyagi, Renu Saxena
    Blood Cells, Molecules, and Diseases.2020; 84: 102445.     CrossRef
  • Procalcitonin as a Diagnostic Marker for Bacteremia in Terminal Cancer Patients
    Jungeun Kim, Youn Seon Choi, Juneyoung Lee, In Cheol Hwang
    Korean Journal of Clinical Geriatrics.2020; 21(1): 16.     CrossRef
  • Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients
    Amanda G. Blouin, Meier Hsu, Martin Fleisher, Lakshmi V. Ramanathan, Stephen M. Pastores
    Clinica Chimica Acta.2020; 510: 181.     CrossRef
  • Diagnostic Accuracy of Procalcitonin, Neutrophil-to-Lymphocyte Ratio, and C-Reactive Protein in Detection of Bacterial Infections and Prediction of Outcome in Nonneutropenic Febrile Patients with Lung Malignancy
    Shanshan Ding, Jun Ma, Xingguo Song, Xiaohan Dong, Li Xie, Xianrang Song, Lisheng Liu
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department
    Ignacio Español-Morales, María Dolores Albaladejo-Otón, Ana Hernando-Holgado, Enrique Jiménez-Santos, Patricia Esteban-Torrella, Pablo Cerezuela-Fuentes, Luis García de Guadiana-Romualdo
    Biochemia medica.2019; 29(1): 57.     CrossRef
  • Combination of sepsis biomarkers may indicate an invasive fungal infection in haematological patients
    Igor Stoma, Igor Karpov, Anatoly Uss, Svetlana Krivenko, Igor Iskrov, Natalia Milanovich, Svetlana Vlasenkova, Irina Lendina, Kristina Belyavskaya, Veronika Cherniak
    Biomarkers.2019; 24(4): 401.     CrossRef
  • Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies
    Mina Yang, Seung Jun Choi, Jaewoong Lee, Dong Gun Lee, Yoon-Joo Kim, Yeon-Joon Park, Eun-Jee Oh, Senthilnathan Palaniyandi
    PLOS ONE.2019; 14(12): e0225765.     CrossRef
  • Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies
    Ahmad Baraka, Marwa Zakaria
    International Journal of Hematology.2018; 108(2): 184.     CrossRef
  • Diagnostic value of sepsis biomarkers in hematopoietic stem cell transplant recipients in a condition of high prevalence of gram-negative pathogens
    Igor Stoma, Igor Karpov, Anatoly Uss, Oleg Rummo, Natalia Milanovich, Igor Iskrov
    Hematology/Oncology and Stem Cell Therapy.2017; 10(1): 15.     CrossRef
  • Comparison of diagnostic and prognostic utility of lactate and procalcitonin for sepsis in adult cancer patients presenting to emergency department with systemic inflammatory response syndrome
    Esra Keçe, Elif Yaka, Serkan Yılmaz, Nurettin Özgür Doğan, Cansu Alyeşil, Murat Pekdemir
    Turkish Journal of Emergency Medicine.2016; 16(1): 1.     CrossRef
  • The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia
    Melis Sirinoglu, Ahmet Soysal, Ayşe Karaaslan, Eda Kepenekli Kadayifci, Ismail Cinel, Ahmet Koç, Gülnur Tokuç, Ali Yaman, Goncagül Haklar, Önder Şirikçi, Serap Turan, Gülşen Altınkanat Gelmez, Güner Söyletir, Mustafa Bakır
    Pediatric Hematology and Oncology.2016; 33(3): 200.     CrossRef
  • Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia
    Xiao Liu, Dao Feng Wang, Yi Fang, Wen Feng Ye, Shu Liu, Ning Lou
    Leukemia & Lymphoma.2015; 56(1): 85.     CrossRef
  • Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6
    Luis García de Guadiana-Romualdo, Ignacio Español-Morales, Pablo Cerezuela-Fuentes, Luciano Consuegra-Sánchez, Ana Hernando-Holgado, Patricia Esteban-Torrella, Enrique Jiménez-Santos, Monserrat Viqueira-González, África de Béjar-Almira, María Dolores Alba
    Supportive Care in Cancer.2015; 23(7): 2175.     CrossRef
  • Adrenomedullin—A New Marker in Febrile Neutropenia: Comparison With CRP and Procalcitonin
    Metin Demirkaya, Deniz Tugcu, Arzu Akcay, Gönül Aydogan, Ferhan Akıcı, Zafer Salcioglu, Hakan Ekmekci, Betül Sevinir, Ozlem Balci Ekmekci
    Pediatric Hematology and Oncology.2015; 32(7): 482.     CrossRef
  • Utilización de procalcitonina y proteína C reactiva como marcadores de infección en la neutropenia febril de pacientes sometidos a trasplante de progenitores hematopoyéticos
    Marina Sánchez-Yepes, Eduardo Aznar-Oroval, Pablo Lorente-Alegre, Tomás García-Lozano, Isabel Picón-Roig, Pilar Pérez-Ballestero, Blanca Ortiz-Muñoz
    Enfermedades Infecciosas y Microbiología Clínica.2014; 32(7): 418.     CrossRef
  • Predictive factors of bacteremia in patients with febrile urinary tract infection: an experience at a tertiary care center
    H. Lee, Y.-S. Lee, R. Jeong, Y.-J. Kim, S. Ahn
    Infection.2014; 42(4): 669.     CrossRef
  • Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: The role of procalcitonin
    Hiroshi Yaegashi, Kouji Izumi, Yasuhide Kitagawa, Yoshifumi Kadono, Hiroyuki Konaka, Atsushi Mizokami, Mikio Namiki
    International Journal of Urology.2014; 21(1): 104.     CrossRef
  • Utilidad de la procalcitonina para predecir bacteriemia en pacientes oncológicos con fiebre
    Enrique Jiménez-Santos, Ana Hernando-Holgado, Luis García de Guadiana-Romualdo, Monserrat Viqueira-González, Pablo Cerezuela Fuentes, Ignacio Español Morales
    Revista del Laboratorio Clínico.2014; 7(4): 127.     CrossRef
  • The Utility of Proadrenomedullin and Procalcitonin in Comparison to C-Reactive Protein as Predictors of Sepsis and Bloodstream Infections in Critically Ill Patients With Cancer*
    Labib Debiane, Ray Y. Hachem, Iba Al Wohoush, William Shomali, Ramez R. Bahu, Ying Jiang, Anne-Marie Chaftari, Joseph Jabbour, Munirah Al Shuaibi, Alexander Hanania, S. Egbert Pravinkumar, Philipp Schuetz, Issam Raad
    Critical Care Medicine.2014; 42(12): 2500.     CrossRef
  • Utility of C-Reactive Protein and Procalcitonin for Detecting Bloodstream Infection in Patients with HIV/AIDS
    Arianna Castillo Marshall, Tersilia García Castellanos, Isabel Martínez Motas, Daniel Salazar Rodriguez, María Eugenia Toledo Romaní, Jorge Pérez Ávila
    World Journal of AIDS.2014; 04(03): 287.     CrossRef
  • The Use of Procalcitonin in Clinical Practice
    Clementine YF Yap, Tar Choon Aw
    Proceedings of Singapore Healthcare.2014; 23(1): 33.     CrossRef
  • Is Procalcitonin Reduction Indicative of Immunomodulation in Septic Patients Treated with Hemodialysis with High Cutoff Membrane?
    Gianluca Villa, Paola Di Maggio, A. Raffaele De Gaudio
    Blood Purification.2014; 38(2): 100.     CrossRef
  • Utilidad de la procalcitonina en la detección de bacteriemia en los pacientes con cáncer
    E. Aznar-Oroval, M. Sánchez-Yepes, T. García-Lozano, B. Ortiz-Muñoz, P. Pérez-Ballestero
    Revista Clínica Española.2013; 213(5): 267.     CrossRef
  • The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients
    Jean Klastersky, Marianne Paesmans
    Supportive Care in Cancer.2013; 21(5): 1487.     CrossRef
  • Diagnostic Value and Prognostic Significance of Pleural C-Reactive Protein in Lung Cancer Patients with Malignant Pleural Effusions
    Do-Sim Park, Dong Kim, Ki-Eun Hwang, Yu-Ri Hwang, Chul Park, Chang-Hwan Seol, Kyung-Hwa Cho, Byoung-Ryun Kim, Seong-Hoon Park, Eun-Taik Jeong, Hak-Ryul Kim
    Yonsei Medical Journal.2013; 54(2): 396.     CrossRef
  • Streamlining antibiotic therapy with procalcitonin protocols: consensus and controversies
    Sebastian Haubitz, Beat Mueller, Philipp Schuetz
    Expert Review of Respiratory Medicine.2013; 7(2): 145.     CrossRef
  • The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies
    Selçuk Kaya, Iftihar Köksal, Ahmet Menteşe, Mehmet Sönmez, Ayşegül Sümer, Seval Sönmez Yıldırım, Gürdal Yılmaz
    International Journal of Infectious Diseases.2013; 17(11): e1056.     CrossRef
  • Procalcitonin in sepsis and bacterial infections
    Abhijit Chaudhury, G.L. Sachin Sumant, R. Jayaprada, Usha Kalawat, B.V. Ramana
    Journal of Clinical & Scientific Research.2013; 2(4): 216.     CrossRef
  • Procalcitonin as a marker of infection in febrile neutropenia: A systematic review
    Anders K. Boysen, Bettina R. Jensen, Laurids Ø. Poulsen, Paw Jensen, Søren Ladefoged
    Modern Chemotherapy.2013; 02(01): 8.     CrossRef
  • Can procalcitonin distinguish infectious fever from tumor‐related fever in non‐neutropenic cancer patients?
    William Shomali, Ray Hachem, Anne‐Marie Chaftari, Ying Jiang, Ramez Bahu, Joseph Jabbour, Sammy Raad, Munirah Al Shuaibi, Iba Al Wohoush, Issam Raad
    Cancer.2012; 118(23): 5823.     CrossRef
  • Allergic Airway Inflammation Initiates Long-Term Vascular Remodeling of the Pulmonary Circulation
    Kristina Rydell-Törmänen, Lena Uller, Jonas S. Erjefält
    International Archives of Allergy and Immunology.2009; 149(3): 251.     CrossRef
  • 13,259 View
  • 155 Download
  • 37 Crossref
Close layer
Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea
Jae-Lyun Lee, Jeong Eun Kim, Jin-Hee Ahn, Dae-Ho Lee, Jungshin Lee, Choung-Soo Kim, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Hanjong Ahn
Cancer Res Treat. 2010;42(1):12-17.   Published online March 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.1.12
AbstractAbstract PDFPubReaderePub
Purpose

To assess the efficacy and safety of treating Korean patients with metastatic hormone-refractory prostate cancer (HRPC) using docetaxel plus prednisolone chemotherapy.

Materials and Methods

This was a retrospective cohort study performed in 98 patients with metastatic HRPC between October 2003 and April 2008. After screening, 72 patients fit the eligibility criteria for inclusion in this study. Treatment consisted of 5 mg prednisolone twice daily and 75 mg/m2 docetaxel once every 3 weeks.

Results

Patient demographic characteristics included: median age 67 years (range, 51~86), median ECOG performance status 1 (0~2), Gleason score ≥8 in 61 patients (86%), and median serum PSA 45.5 ng/mL (range, 3.7~2,420.0). A total of 405 cycles of treatment were administered with a median 6 cycles (range, 1~20) per patient. The median docetaxel dose-intensity was 24.4 mg/m2/week (range, 17.5~25.6). A PSA response was seen in 51% of 63 evaluable patients at 12 weeks and maximal PSA decline ≥50% in 59% of 70 evaluable patients. Tumor response was evaluated in 13 patients, 4 patients achieved PR, and 5 patients had SD with a response rate of 31%. With a median follow-up duration of 23.1 months (95%CI, 16.7~29.5), the median time to PSA progression was 5.1 months (95%CI, 4.5~5.8) and median overall survival was 22.8 months (95%CI, 16.6~29.1). Nine (13%) patients experienced grade 3 or higher febrile neutropenia.

Conclusion

This chemotherapy regimen (docetaxel every 3 weeks plus prednisolone daily) demonstrated a strong response in Korean patients with metastatic HRPC, while the toxicity profile was manageable and similar to that observed in Western patients.

Citations

Citations to this article as recorded by  
  • Modulation of inflammatory mediators underlies the antitumor effect of the combination of morusin and docetaxel on prostate cancer cells
    Sana A. Fadil, Dina A.I. Albadawi, Khalid Z. Alshali, Hossam M. Abdallah, Mona M. Saber
    Biomedicine & Pharmacotherapy.2024; 180: 117572.     CrossRef
  • Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
    Kwonoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Hyo Jin Lee, Jae Lyun Lee
    Yonsei Medical Journal.2023; 64(2): 86.     CrossRef
  • Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer
    Bumjin Lim, Wonchul Lee, Yoon Soo Kyung, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
    Journal of Cancer Research and Clinical Oncology.2022; 148(3): 727.     CrossRef
  • AN INDIAN PROSPECTIVE STUDY OF DOCETAXEL THERAPY IN CRPC: CAN PRETREATMENT FACTORS PREDICT THE RESPONSE
    Devashish Kaushal, Rajeev Sood
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 78.     CrossRef
  • A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
    Seonggyu Byeon, Hongsik Kim, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Soon Il Lee, Se Hoon Park
    BMC Cancer.2021;[Epub]     CrossRef
  • Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
    Myung-Won Lee, Hyewon Ryu, Ik-Chan Song, Hwan-Jung Yun, Deog-Yeon Jo, Young Bok Ko, Hyo-Jin Lee
    Medicine.2020; 99(17): e19931.     CrossRef
  • A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
    Sang Eun Yoon, Youjin Kim, Jangho Cho, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byoung Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Su Jin Lee, Se Hoon Park
    BMC Urology.2019;[Epub]     CrossRef
  • Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells
    Chongyi Yang, Weijie Zhang, Jie Wang, Pengpeng Chen, Jiangjiang Jin
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer
    Hiromi Sato, Shintaro Narita, Norihiko Tsuchiya, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Kyoko Nomura, Tomonori Habuchi
    BMC Urology.2018;[Epub]     CrossRef
  • A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
    Hae Su Kim, Ji Yun Lee, Su Jin Lee, Ho Yeong Lim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Se Hoon Park
    BMC Urology.2017;[Epub]     CrossRef
  • Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer
    Dong Hoon Lee, Jung Ho Kim, Won Ik Seo, Jong Kil Nam, Tae Nam Kim, Cheol Kyu Oh, Soo Dong Kim, Sung-Woo Park, Jae Sung Chung, Sang Hyun Park, Wan Lee, Gyung Tak Sung, Moon Kee Chung, Jae Il Chung
    The Korean Journal of Urological Oncology.2017; 15(2): 59.     CrossRef
  • Hormonal therapy and chemotherapy for advanced prostate cancer
    Jae Lyun Lee
    Journal of the Korean Medical Association.2015; 58(1): 30.     CrossRef
  • Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
    J-L Lee, J-H Ahn, M K Choi, Y Kim, S-W Hong, K-H Lee, I-G Jeong, C Song, B-S Hong, J H Hong, H Ahn
    British Journal of Cancer.2014; 110(10): 2472.     CrossRef
  • Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program
    Jae-Lyun Lee, Se Hoon Park, Su-Jin Koh, Se Hoon Lee, Yu Jung Kim, Yoon Ji Choi, Jihye Lee, Ho Yeong Lim
    Cancer Chemotherapy and Pharmacology.2014; 74(5): 1005.     CrossRef
  • Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer
    Whi-An Kwon, Tae Hoon Oh, Jae Whan Lee, Seung Chol Park
    Asian Pacific Journal of Cancer Prevention.2014; 15(8): 3443.     CrossRef
  • Clinical predictor of survival following docetaxel-based chemotherapy
    HSIANG-YING LEE, WEN-JENG WU, CHUN-HSIUNG HUANG, YII-HER CHOU, CHUN-NUNG HUANG, YUNG-CHIN LEE, KAI-FU YANG, MEI-HUI LEE, SHU-PIN HUANG
    Oncology Letters.2014; 8(4): 1788.     CrossRef
  • Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
    Geehyun Song, Chunwoo Lee, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
    Prostate International.2013; 1(3): 125.     CrossRef
  • Quimioterapia sistémica basada en docetaxel en hombres coreanos mayores con cáncer de próstata resistente a la castración
    S.C.H. Park, L.J. Whan, R.J. Sik
    Actas Urológicas Españolas.2012; 36(7): 425.     CrossRef
  • Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer
    S.C.H. Park, L.J. Whan, R.J. Sik
    Actas Urológicas Españolas (English Edition).2012; 36(7): 425.     CrossRef
  • 11,593 View
  • 73 Download
  • 19 Crossref
Close layer
The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia
Young Joo Min, Cheol Won Suh, Keon Uk Park, Sung Soo Yoon, Chan Hyung Park, Hong Ghi Lee
Cancer Res Treat. 2003;35(1):66-68.   Published online February 28, 2003
DOI: https://doi.org/10.4143/crt.2003.35.1.66
AbstractAbstract PDF
PURPOSE
This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML). MATERIALS AND METHODS: After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days. RESULTS: The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%). CONCLUSION: The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML.
  • 3,996 View
  • 25 Download
Close layer
The Effectiveness and Safety of DA-3030 ( rhG-CSF ) for Chemotherapy - induced Neutropenia: A Randomized Controlled Trial
Dae Ho Lee, Cheolwon Suh, Keunchil Park, Tae Won Kim, Jung Gyun Kim, Won Seog Kim, Won Ki Kang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
J Korean Cancer Assoc. 1999;31(5):995-1002.
AbstractAbstract PDF
PURPOSE
We investigated the effectiveness and safety of DA-3030 for prophylatic use in patients receiving chemotherapy for malignant disease.
MATERIALS AND METHODS
Seventy cancer patients were randomized to receive chemotherapy alone (36 patients) or with DA-3030 administered (34 patients) after stratified block randomization according to chemotherapeutic regimen. DA-3030 was subcutaneously administered at the dose of 100 pg/m/day for 10 days from 24 hours after the completion of chemotherapy.
RESULTS
Of the 70 enrolled patients, 62 patients were evaluable. The neutropenia (absolute neutrophil count [ANC] <1,000/mm) occurred in 9 of 32 (28.1%) of the DA-3030 group and 21 of 30 (90.0%) of the control group, giving relative risk for control group of 0.154 (95% confidence interval [CI], 0.05 to 0.45; p-0.0001). Severe neutropenia (ANC 500/mm') occurred in 4 of 32 (12.5%) of the DA-3030 group and in 20 of 30 (66.7%) of the control group (relative risk for control group of 0.316 [95% CI, 0,18 to 0.55]; p=0.0001). The mean duration of neutropenic period (+/-standard error) was 1.13+/-0.34 days in the DA-3030 group and 6.73+/-0.69 days in the control group respectively, and was significantly shorter in the DA-3030 group (p<0.0001). And, there was higher nadir ANC in the OA-3030 group than that in the control group (p=0.0001); the mean nadir ANC was 2,547+/- 343/mm and 442+/-120/mm, respectively. The DA-3030 group had significantly higher incidence of myalgia in comparison to the control group (43.8% compared with 3.3%; p=0.001). However, it was tolerable and was easily managed by conservative therapy CONCLUSION: The use of DA-3030 was effective in preventing chemotherapy-induced neutropenia.
  • 2,824 View
  • 19 Download
Close layer
Four Cases of Typhlitis, Developed in Neutropenic State and Treated with Medical Conservative Management
Pill Woon Kim, Hyeon Gyoo Ji, Hyun Sik Jeong, Chan Il Moon, Dong Kyeong Yang, Seung Won Lee, Yon Sil Jung, Ji Ho Choi, Gui Hyun Nam, Jae Hoon Lee, Dong Bok Shin
J Korean Cancer Assoc. 1997;29(5):906-913.
AbstractAbstract PDF
Typhlitis is a life threatening necrotizing enterocolitis of the cecum, ascending colon and terminal ileum seen in severely neutropenic patients, however its pathogenesis is not identified up to this time.The incidence of typhlitis in leukemic patient is 10~12%, estimated by postmortem examination, and 46% in induction chemotherapy of leukemia. Recently, entity incidence is more high due to increasing challenges to high dose chemotherapy in solid tumors.We experienced four cases of typhlitis, one was developed in the circumstance of neutropenia induced by induction chemotherapy for acute myelocytic leukemia and others in neutropnia due to primary diseases without chemotherapy, ig, chronic myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome.All cases were treated with high dose broad spectrum antibiotics in early phase of disease and its outcome was good, so that, early diagnosis of typhlitis is essential, then prompt treatment with high dose antibiotics and intravenous fluid before onset of transmural necrosis is associated with lower morbidity and mortality than surgical resection.
  • 2,820 View
  • 23 Download
Close layer
Effect of Filgrastim ( rhG - CSF ) on Chemotherapy Induced Neutropenia in Pediatric Acute Myelogenous Leukemia Patients
Hee Young Shin, Hee Young Shin, Seong Hoon Hah, Hong Hoe Koo, Hyo Seop Ahn
J Korean Cancer Assoc. 1994;26(1):136-144.
AbstractAbstract PDF
To determine the safety and efficacy of rhG-CSF on chemotherapy induced neutropenia in pediatric AML patients, we conducted a prospective controlled study in 17 patiens with AML at Seoul National University Childrens Hospital from July, 1993 to January, 1994. High dose cytosine arabinoside(Ara-C, 3gm/m for four times every 12 hours) with L-asparaginase 6,000 u/m) were given to 13 patients as Group I control and after the recovery of WBC, same chemo- therapy followed by G-CSF(50 ug/m for 10 days) were given as Group I study. In Group II study, high dose Ara-C(3gm/m(2) for 8 times every 12 hours) were given to 11 patients with AML followed by G-CSF(150 ug/m for 10 days). Recovery of the absolute neutrophil counts to more than 1,000/mm' was significantly faster in the G-CSF group than in the control group(P< 0.01) and the absolute neutrophil counts on day 14 of chemotherapy was significantly higher in G-CSF group(P<0.01). The toxicity of G-CSF was minimal and there was no evidence of accel- erated growth of leukemic blasts during the G-CSF treatment. In conclusion, Filgrastim(rhG- CSF) promotes the recovery of neutrophils and shortens the duration of neutropenia induced by the chemotherapy in pediatric acute myelogenous leukemia.
  • 2,644 View
  • 19 Download
Close layer
The Effects of Granulocyte Colony Stimulating Factor on Neutropenia Induced by the Chemotherapy in the Solid Tumor Patient
Sang Won Shin, Young Jin Nam, Chul Won Choi, Gwan Gyu Song, Jun Suk Kim, Soon Duck Kim, Yeul Hong Kim
J Korean Cancer Assoc. 1994;26(1):144-151.
AbstractAbstract PDF
We evaluated the effect of aranulocyte colony stimulating factor (G-CSF) to prevent chemo- therapy induced neutropenia and fever development during neutropenic period. The twenty patients with solid tumor were treated with various cytotoxic chemotherapeutic agents at least two cycles. The patients were given G-CSF 75pg/day after 2nd cycle chemotherapy for least 14 consecutive days and clinical, laboratory results were compared to the first cycle's results. Treatment with G-CSF resulted in increase of mean neutrophil count(320+-230/mm(3) vs 1030 +-1020/mm(2)), reduced the duration of neutropenic days(4.25 dyas vs 1.30 days, absolute neutrophil count less than 500/mm) snd reduced the incidence of neutropenic fever(75% vs 25% ). The side effect af G-CSF was not so significant. These results demonsrated that the use of G-CSF as an adjunct to chemotherapy with various solid cancer patients was well tolerated and led to reduction in the incidence of neutropenic fever; in the terms of incidence, duratian, and severity of neutropenia.
  • 2,713 View
  • 15 Download
Close layer
Grnulocyte Colony - Stimulating Factor , Filgrastim ( G - CSF , Filgastrim ) in Acute Leukemia after Remission Induction Chemotherapy
Cheol Won Suh, Sung Bae Kim, Sang Hee Kim, Young Ran Chae, Byoug Soon Doh, Sang We Kim, Myung Ju Ahn, Kyoo Hyung Lee, Jung Shin Lee
J Korean Cancer Assoc. 1994;26(3):431-438.
AbstractAbstract PDF
Objectives
Colony stimulating factors have been shown to accelerate recovery from severe neutropenia after intensive chemotherapy. To prove its clinical effectiveness, we conducted controlled study to administer G-CSF in acute leukemia after induction chemotherapy. Methods: Forty patients with newly diagnosed and relapsed or refractory acute leukemia after remission induction chemotherapy were randomly assigned to one of two groupa (20 G- CSF treated group, 20 control grouP). Treatment with G-CSF(200 ug/m(2)/d) was started 48 hours after the end of chemotherapy and continued until the neutrophil count rose above 1,500 /mm(3). Results: Treatment with G-CSF shortened neutropenic period after chemotherapy, i.e., median duration of neutrophil counts less than 1,000/mm(3) was 21 days in control group and 12 days in G-CSF treated group. The incidence of infection was 80%in control group, 70% in G-CSF treated group, but it did not show any statistically significant difference. Microbiologically documented infection was 40% in control group, 20% in G-CSF treated group. Febrile periods and duration of antibiotic administration were decreased to 7 days and 18 days respectively. In G- CSF treated group, two Patients reported mild bone pain. There was no evidence that G-CSF could increase remission duratian and survival. Conclusion: It appears that recombinant G-CSF is safe and useful in neutropenic patients after intensive chemotherapy, accelerating neutrophil recovery and thereby reducing the incidence of documented infection and duration of antibiotic ad#ministration.
  • 3,104 View
  • 18 Download
Close layer
Effect of rhGM-CSF on the Chemotherapy - induced Neutropenia of Children with Solid Tumors
Jong Jin Seo, Sang Won Cha, Sang Mee Lee, Kyu Don Kim
J Korean Cancer Assoc. 1995;27(2):322-331.
AbstractAbstract PDF
To investigate the clinical effectiveness of recombinant human GM-CSF(rhGM-CSF; Leucogen) on the chemotherapy-induced neutropenia, twelve children with malignant solid tumor who had neutropenia after chemotherapy received 250 pg/M(2)/day of rhGM-CSF subcutaneouly for 10 consecutive days from the fifth day of next chemotherapy were schedule using the same rekimen. rhGM-CSF significantly increased leukocyte, neutrophil and eosinophil counts on the tenth day of GM-CSF course compared to the control course(P<0.05), but there was no significant difference in the counts of monocyte, lymphocyte, platelet or hemoglobin(p>0.1). The nadir of leukocyte and neutrophil were significantly higher in GM-CSF course than those of control course (P<0.05), but there was no significant difference in that of monocyte, lymphocyte, eo- sinophil, platelet or hemoglobin(P: 0.1). The duration of chemotherapy-induced leukopenia and neutropenia were decreased significantly in GM-CSF course than those of control course(P< 0.05). The duration of antibiotics administration and febrile period during chemotherapy were shorter in GM-CSF course without statistical significance. No significant side effect was observed during rhGM-CSF course. These results indicate that rhGM-CSF(Leucogen') is effective in alleviating the chemotherapy-induced neutropenia of children with malignant solid tumors.
  • 2,705 View
  • 21 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP